natgillin/translations-raw huggingface dataset:
thioridazine, a medicine used in the treatment of schizophrenia and psychosis, that may affect the heart, certain medicines for depression, called monoamine oxidase inhibitors (MAOIs- for example phenelzine and moklobemide).
tioridazin, zdravilo, ki ga uporabljamo za zdravljenje shizofrenije in psihoze, ki lahko vpliva na srce; določena zdravila za depresijo, imenovana zaviralci monoamin-oksidaze (MAOI, npr. fenelzin in moklobemid).
Thiotepa might induce pulmonary toxicity that may be additive to the effects produced by other cytotoxic agents (busulfan, fludarabine and cyclophosphamide) (see section 4.8).
Tiotepa lahko povzroči pljučno toksičnost, kar lahko prispeva k učinkom drugih citotoksičnih snovi (busulfana, fludarabina in ciklofosfamida) (glejte poglavje 4.8).
Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment.
Tiotepa se ne sme uporabljati hkrati s ciklofosfamidom, ko sta obe zdravili prisotni v istem pripravljalnem zdravljenju.
Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment.
Tiotepa se ne sme uporabljati hkrati s ciklofosfamidom, če sta obe zdravili prisotni v istem pripravljalnem zdravljenju.
Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment.
Tiotepe se ne sme uporabljati hkrati s ciklofosfamidom, ko sta obe zdravili prisotni v istem pripravljalnem zdravljenju.
Third
tretje
Third
tretjič
Third dose (12 months after the second dose)
Tretji odmerek (12 mesecev po drugem odmerku)
Third episode: reduce docetaxel dose by 20%.
Tretji pojav: zmanjšajte odmerek docetaksel za 20 %.
Third episode: reduce docetaxel dose by 20%.
tretji pojav: zmanjšajte odmerek docetaksela za 20
Third injection: 6 months after first injection
Tretja injekcija: 6 mesecev po prvi injekciji
Third injection: 6 months after first injection (not earlier than 3 months after the second dose) All three doses should be given within a 1-year period.
Tretja injekcija: 6 mesecev po prvi injekciji (ne prej kot 3 mesece po drugem odmerku) Vse tri odmerke je treba dati v obdobju 1 leta.
Third monthly weighing where bodyweight loss < 3% per month since previous weighing
Tretje mesečno tehtanje, kjer je izguba telesne mase < 3 % na mesec v primerjavi s prejšnjim mesečnim tehtanjem
Third occurrence
tretji pojav
Third occurrence:
Tretji pojav:
Third trimester of pregnancy (n=11)
Tretje trimesečje nosečnosti (n=11)
Third Trimester of pregnancy (n=14)
Tretje trimesečje nosečnosti (n=14)
Third, follow the procedure below for compounding the 6 mg/ml suspension from Ebilfumin capsules:
Nazadnje za pripravo 6 mg/ml suspenzije iz kapsul zdravila Ebilfumin sledite spodnjemu postopku:
Third, follow the procedure below for compounding the 6 mg/ml suspension from Tamiflu capsules:
Nato za pripravo 6 mg/ml suspenzije iz kapsul zdravila Tamiflu sledite spodnjemu postopku:
Third, follow the procedure below for compounding the 6 mg/ml suspension from Tamiflu capsules:
Nazadnje za pripravo 6 mg/ml suspenzije iz kapsul zdravila Tamiflu sledite spodnjemu postopku:
Thirst
Bolezni dihal
Thirst
žeja
thirst
žeja,
Thirst
žeja;
thirst (dehydration)
žeja (dehidracija)
thirst (dehydration)
žeja (dehidracija),
Thirst in hot weather
žeja v vročem vremenu
thirst nausea
žeja siljenje na bruhanje
thirst tooth disorder.
žeja, bolezni zob.
thirst, dry skin, irritability, dark urine, decreased urine output (signs of kidney disorders)
žeja, suha koža, razdražljivost, temen urin, zmanjšano izločanje urina (znaki ledvičnih bolezni)
thirst, fatigue.
žeja, utrujenost
Thirst, feeling hot
žeja, občutek vročine;
Thirst, glycosuria, hyperglycaemia
žeja, glukozurija, hiperglikemija
Thirst, increased need to urinate (pee), tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heart beat, and glucose and ketone bodies in urine.
Žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heart beat and, glucose and ketone bodies in urine.
Žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heart beat, and glucose and ketone bodies in urine.
Kot znaki previsokega krvnega sladkorja se lahko pojavijo žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heart beat, and, glucose and ketone bodies in urine.
Žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
Thirst, low urine output, dark urine, dry flushed skin, irritability (signs of dehydration)
žeja, zmanjšano izločanje urina, temen urin, suha pordela koža, razdražljivost (znaki dehidracije)
Thirteen of these ONJ cases occurred in postmenopausal women with osteoporosis during the phase III clinical trial extension following treatment with Prolia for up to 10 years (0.3%; < 0.1 events per 100 subject-years).
Trinajst od teh primerov osteonekroze čeljustnice se je pojavilo pri ženskah po menopavzi z osteoporozo med podaljšanjem kliničnega preskušanja III. faze po zdravljenju z zdravilom Prolia do 10 let (0,3 %; < 0,1 dogodek na 100 preiskovancev-let).
Thirteen patients (3%) receiving sunitinib in the phase 3 treatment-naïve MRCC study and four patients (2%) on the two cytokine-refractory MRCC studies had venous thromboembolic events reported.
O venskih trombemboličnih dogodkih so poročali pri 13 bolnikih (3 %), ki so sunitinib prejemali v 3. fazi študije pri še nezdravljenem MRCC, in pri 4 bolnikih (2 %) v dveh študijah MRCC, odpornega proti citokinom.
Thirteen percent (6/45) of the tenofovir disoproxil fumarate group, 13% (6/45) of the emtricitabine plus tenofovir disoproxil fumarate group, and 9% (2/22) of the entecavir group had a confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl.
Trinajst odstotkov (6/45) v skupini z dizoproksiltenofovirijevim fumaratom, 13% (6/45) v skupini z emtricitabinom in dizoproksiltenofovirijevim fumaratom in 9% (2/22) v skupini z entekavirjem je imelo potrjeno zvišanje serumske koncentracije kreatinina za ≥ 0,5 mg/dl ali potrjeno serumsko koncentracijo fosfata < 2 mg/dl.
Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites.
13% odmerka emtricitabina je iz urina izoliranega v obliki treh metabolitov.
Thirty (30) of the 43 Revestive-treated patients from the pivotal study who entered the extension study completed a total of 30 months of treatment.
Trideset (30) od 43 bolnikov, ki so bili zdravljeni z zdravilom Revestive iz ključne študije,ki so bili vključeni v podaljšano študijo, je zaključilo skupno 30 mesecev zdravljenja.
Thirty minutes after administration of the test solution (point 7), collect the 30-minute-value samples in the two containers which are left in the test package (Label “Sampling time:
Trideset minut po zaužitju testne raztopine zberite vzorca 30-minutnih vrednosti v preostala lončka (oznaka: "
Thirty minutes after administration of the test solution (point 7), collect the 30-minute-value samples in the two containers which are left in the test package (Label “Sampling time:
Trideset minut po zaužitju testne raztopine zberite vzorca 30-minutnih vrednosti v preostala vsebnika (oznaka: "
Thirty two (32) evaluable paediatric patients crossed over (9 subjects in the q8 weeks and 23 subjects in the q12 weeks maintenance groups).
32 pediatričnih bolnikih (pri 9 preiskovancih iz skupine za vzdrževalno zdravljenje z infuzijami na vsakih 8 tednov in pri 23 preiskovancih iz skupine z infuzijami na vsakih 12 tednov).
Thirty-five percent of patients were on a treatment regimen that did not contain tenofovir disoproxil fumarate.
Petintrideset bolnikov je bilo na režimu zdravljenja, ki ni vseboval dizoproksiltenofovirat fumarata.
Thirty-four percent of patients were enrolled on comorbidity score alone, and 23% of patients were enrolled with only impaired renal function.
34 % bolnikov je bilo vključenih le zaradi ocene komorbidnosti in 23 % le zaradi okvare delovanja ledvic.
Thirty-nine patients (39%) discontinued the study, including 16 (16%) discontinuations due to adverse events, one of which was associated with a death.
Devetintrideset bolnikov (39%) je prenehalo s študijo, vključno s 16 (16%) prenehanji zaradi neželenih dogodkov, eden izmed teh je bil povezan s smrtjo.
Thirty-one percent (31%) of patients in studies were documented as having palpable splenomegaly.
Pri 31 % bolnikov, vključenih v študije, so dokumentirali tipljivo splenomegalijo.
Thirty-one percent (31%) of patients in studies were documented as having palpable splenomegaly.
V študijah je 31 % bolnikov imelo tipljivo splenomegalijo.
Thirty-one percent (31%) of patients in studies were documented as having palpable splenomegaly.
V študijah so dokumentirali, da je imelo 31 % bolnikov tipljivo splenomegalijo.
Thirty-one percent had an ECOG Performance Status of 1, 69% had ECOG Performance Status of 0 and 32% had elevated LDH.
Enaintrideset odstotkov bolnikov je imelo telesno zmogljivost po ECOG 1, 69 % je imelo telesno zmogljivost po ECOG 0 in 32 % jih je imelo zvišan LDH.
Thirty-one percent of patients had been treated with prior HCV therapies, primarily pegylated interferon plus ribavirin.
31 % bolnikov je bilo že predhodno zdravljenih za HCV, primarno z pegiliranim interferonom in ribavirinom.
Thirty-three (18%) of patients were treated concomitantly with disease modifying anti-rheumatic drugs, and 146 (79%) patients with NSAIDs at baseline.
33 (18 %) bolnikov je bilo na začetku sočasno zdravljenih z modifikatorji bolezni ali protirevmatskimi zdravili in 146 (79 %) bolnikov z nesteroidnimi antirevmatiki.
Thirty-two of 189 (17%) patients underwent allogeneic HSCT in CR/CRh* induced with BLINCYTO (see table 1).
Dvaintridesetim od 189 (17 %) bolnikov so opravili alogensko presaditev krvotvornih matičnih celic med CR/CRh*, doseženo z zdravilom BLINCYTO (glejte tabelo 1).
Thirty-two percent of patients had BRAF mutation-positive melanoma; 26.5% of patients had PD-L1
Dvaintrideset bolnikov je imelo melanom, ki je bil pozitiven za mutacijo BRAF, 26,5 % bolnikov je imelo PD-L1
Thirty-two percent of patients had deletion 17p and 31% had 11q deletion.
Dvaintrideset odstotkov bolnikov je imelo prisotno delecijo 17p, 31% pa jih je imelo delecijo 11q.
Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).
Dvaintrideset odstotkov celotnega peroralnega odmerka se izloči z urinom, bodisi v obliki dolutegravirjevega glukuronida (18,9 % celotnega odmerka), metabolita N- dealkilacije (3,6 % celotnega odmerka) in metabolita, ki nastane z oksidacijo na benzilnem ogljiku (3,0 % celotnega odmerka).
This
Pri teh
This
To
This 13C can be detected in the carbon dioxide that you breathe out of your lungs.
Ta 13C je možno ugotoviti v ogljikovem dioksidu, ki ga izdihavate.
This 18 month difference was statistically significant with a hazard ratio of reduction of risk of death in the MPT arm of 0.59, 97.5% confidence interval of 0.42-0.84 and p-value of <0.001 (see Figure 1).
Ta 18-mesečna razlika je bila statistično pomembna z znižanjem razmerja nevarnosti tveganja za smrti v skupini MPT z 0,59; 97,5 %, interval zaupanja 0,42-0,84 in vrednostjo p < 0,001 (glejte sliko 1).
This 21-day period (3 weeks) corresponds to one treatment cycle.
To 21- dnevno obdobje (3 tedni) je en krog zdravljenja.
This 24 hour hold may include up to 6 hours at room temperature (at or below 25°C); any additional hold time must be at 2°C - 8°C. If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.
Teh 24 ur lahko obsega do 6 ur na sobni temperaturi (25 °C ali manj); ves dodatni čas pa mora biti na temperaturi 2 °C - 8 °C. Če so viale in/ali intravenske vrečke shranjene v hladilniku, jih morate pustiti, da pred uporabo dosežejo sobno temperaturo.
This 24 hour hold may include up to 6 hours at room temperature (at or below 25°C); any additional hold time must be at 2°C – 8°C. If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.
Teh 24 ur lahko obsega do 6 ur na sobni temperaturi (25 °C ali manj); ves dodatni čas pa mora biti na temperaturi 2 °C - 8 °C. Če so viale in/ali intravenske vrečke shranjene v hladilniku, jih morate pustiti, da pred uporabo dosežejo sobno temperaturo.
This 24 hour hold may include up to 6 hours at room temperature (at or below 25°C); any additional hold time must be at 2°C – 8°C. If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.
Teh 24 ur lahko obsega do 6 ur na sobni temperaturi (25 °C ali manj); ves dodatni čas pa mora biti na temperaturi 2 °C – 8 °C. Če so viale in/ali intravenske vrečke shranjene v hladilniku, jih morate pustiti, da pred uporabo dosežejo sobno temperaturo.
This 300 mg tablet of clopidogrel is intended for use as a loading dose in patients suffering from acute coronary syndrome:
300-mg tableta klopidogrela je namenjena kot udarni odmerek pri bolnikih z akutnim koronarnim sindromom:
This 4 week period is called a ‘cycle.’ The specific dosing schedule is as follows:
Ti 4 tedni se imenujejo cikel zdravljenja, ki sledi naslednji posebni shemi odmerjanja:
This 4-week period is considered a treatment cycle.
To 3-tedensko obdobje predstavlja en krog zdravljenja.
This 96-week trial is designed to evaluate the safety and efficacy of long-term treatment of lumacaftor/ivacaftor and is ongoing.
To 96-tedensko preskušanje je zasnovano za vrednotenje varnosti in učinkovitosti dolgoročnega zdravljenja z lumakaftorjem/ivakaftorjem in še traja.
This abnormal thinking and behaviour can consist of one or more of a variety of manifestations including abnormal thoughts about reality, delusions, hallucinations (seeing or hearing things that are not real), confusion, disorientation, aggressive behaviour, agitation, and delirium.
To nenormalno mišljenje in vedenje se lahko kaže kot eden ali več različnih znakov, vključno z nenormalnimi mislimi o resničnosti, blodnjami, halucinacijami (videnje ali slišanje stvari, ki niso resnične) , zmedenostjo, dezorientiranostjo, agresivnim vedenjem, vznemirjenostjo in delirijem (bledežem).
This abnormal thinking and behaviour can consist of one or more of a variety of manifestations including abnormal thoughts about reality, delusions, hallucinations (seeing or hearing things that are not real), confusion, disorientation, aggressive behaviour, agitation, and delirium.
To nenormalno mišljenje in vedenje se lahko kaže kot eden ali več različnih znakov, vključno z nenormalnimi mislimi o resničnosti, blodnjami, halucinacijami (videnje ali slišanje stvari, ki niso resnične), zmedenostjo, dezorientiranostjo, agresivnim vedenjem, vznemirjenostjo in delirijem (bledežem).
This absence of drug-drug interaction was confirmed by pharmacokinetic data from the NEOSPHERE trial in the neoadjuvant setting.
Odsotnost medsebojnega delovanja med zdravili je bila potrjena s farmakokinetičnimi podatki študije NEOSPHERE pri neoadjuvantnem zdravljenju.
This action inhibits viral replication or if replication occurs, the progeny virions are unable to leave the cell.
Tako zavira replikacijo virusov, če pa do replikacije kljub temu pride, novi virioni ne morejo zapustiti celice.
This active compound interferes with the parasites’ nervous system and causes paralysis and death.
Ta aktivna spojina vpliva na živčni sistem zajedavcev ter povzroči paralizo in smrt.
This active immune response will help to protect the pig against the disease caused by this virus.
Ta aktivni imunski odziv bo pripomogel pri zaščiti prašiča pred boleznijo, ki jo povzroča ta virus.
This active substance is an antiretroviral or antiviral medicine which is used to treat HIV infection.
Ta zdravilna učinkovina je protiretrovirusno ali protivirusno zdravilo, ki se uporablja za zdravljenje okužbe z virusom HIV.
This active substance is an antiretroviral or antiviral medicine which is used to treat HIV or HBV infection or both.
Ta zdravilna učinkovina je protiretrovirusno ali protivirusno zdravilo, ki se uporablja za zdravljenje okužbe z virusom HIV, okužbe z virusom HBV ali obeh.
This adds up to a 28 day treatment cycle.
To skupaj nanese 28 dni v enem ciklu zdravljenja.
This adds up to a 28-day treatment cycle.
To skupaj nanese 28 dni v enem ciklu zdravljenja.
This adjuvant contains squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
Ta adjuvans vsebuje skvalen (10,69 miligramov), DL--tokoferol (11,86 miligramov) in polisorbat 80 (4,86 miligramov).
This adjuvant contains squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams).
Ta adjuvans vsebuje skvalen (10,69 miligramov), DL-- tokoferol (11,86 miligramov) in polisorbat 80 (4,86 miligramov).
This adjuvant contains squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams).
Ta adjuvans vsebuje skvalen (10,69 miligramov), DL--tokoferol (11,86 miligramov) in polisorbat 80 (4,86 miligramov).
This administration corresponds to free active substance systemic exposure levels of at least 9 times the expected levels in human after 1 month and less than the expected level in humans after 6 months, respectively.
Takšna uporaba ustreza sistemski izpostavljenosti proste zdravilne učinkovine in sicer vsaj 9-kratni pričakovani ravni pri človeku po 1 mesecu in manj kot 1- kratni pričakovani ravni pri človeku po 6 mesecih.
This ADR was not accompanied by clinical symptoms.
Tega neželenega učinka niso spremljali klinični simptomi.
This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea, arthralgia and arthritis with subsequent joint swelling.
Ta neželeni učinek zdravila obsega sklop simptomov, med katerimi so zvišana telesna temperatura, mialgija, glavobol, bolečine v okončinah, navzea, bruhanje, driska, artralgija in artritis z otekanjem sklepov.
This adverse drug reaction was reported as common in patients with controlled blood pressure who were treated with telmisartan for the reduction of cardiovascular morbidity on top of standard care.
Ta neželena reakcija je bila pogosta pri bolnikih z uravnanim krvnim tlakom, katerim so telmisartan predpisali dodatno ob standardnem zdravljenju, da bi zmanjšali zbolevnost za srčnožilnimi boleznimi.
This adverse reaction was reported as common in patients with controlled blood pressure who were treated with telmisartan for the reduction of cardiovascular morbidity on top of standard care.
Ta neželena reakcija je bila pogosta pri bolnikih z uravnanim krvnim tlakom, katerim so telmisartan predpisali dodatno, ob standardnem zdravljenju, da bi zmanjšali zbolevnost za srčnožilnimi boleznimi.
This aggression is potentially treatment related.
Možno je, da je ta agresivnost povezana z zdravljenjem.
This Alert Card contains important safety information that you need to be aware of before and during treatment with Flixabi.
Ta opozorilna kartica vsebuje pomembne varnostne informacije, ki jih morate poznati, preden prejmete zdravilo Flixabi pa tudi med zdravljenjem z njim.
This Alert Card contains important safety information that you need to be aware of before and during treatment with Inflectra.
Ta opozorilna kartica vsebuje pomembne informacije o varnosti, s katerimi morate biti seznanjeni, preden prejmete zdravilo Inflectra in med zdravljenjem s tem zdravilom.
This Alert Card contains important safety information that you need to be aware of before and during treatment with Remicade.
Ta opozorilna kartica vsebuje pomembne varnostne informacije, ki jih morate poznati, preden prejmete zdravilo Remicade pa tudi med zdravljenjem z njim.
This Alert Card contains important safety information that you need to be aware of before and during treatment with Remsima.
Ta opozorilna kartica vsebuje pomembne varnostne informacije, ki jih morate poznati, preden prejmete zdravilo Remsima, pa tudi med zdravljenjem z njim.
This alert card contains important safety information that you need to be aware of before you are given ORENCIA and during treatment with ORENCIA.
Opozorilna kartica za bolnika vsebuje pomembne informacije o varnosti, ki se jih morate zavedati pred začetkom zdravljenja in med zdravljenjem z zdravilom ORENCIA.
This allows a lower dose of indinavir to be used for the same antiviral effect.
To omogoča uporabo manjšega odmerka indinavirja za dosego enakega protivirusnega učinka.
This allows a lower dose of saquinavir to be used for the same antiviral effect.
To omogoča uporabo manjšega odmerka sakvinavirja za dosego enakega protivirusnega učinka.
This allows a lower dose of Telzir to be used for the same antiviral effect.
To omogoča uporabo manjšega odmerka zdravila Telzir za dosego enakega protivirusnega učinka.
This allows blood pressure to drop with a resulting decrease in protein in the urine which may slow down progression of kidney disease.
Zaradi tega se krvni tlak zniža, posledično je manj tudi beljakovin v urinu, kar lahko pripomore k upočasnitvi napredovanja ledvičnega obolenja.
This allows the air inside the cartridge to escape through the needle. o If you attach the needle after Number 3 shows in the window, the pen may not deliver the full dose or may jam.
To omogoči, da gre zrak znotraj vložka ven skozi iglo. o Če iglo namestite, ko je v okencu številka 3, peresnik morda ne bo zagotovil celotnega odmerka ali lahko povzroči zastoj.
This allows the capsule to drop forward into the spinning chamber.
Pri tem kapsula pade naprej v predel za vrtenje.
This allows the difference between normal and abnormal tissue to be seen.
Zaradi tega postane razlika med običajnim in neobičajnim tkivom vidna.
This also applies to any unknown or emerging viruses or other types of infections
To velja tudi za doslej neznane ali na novo pojavljajoče se viruse ali druge oblike okužb.
This also applies to newborn babies and patients with an increased risk of thrombosis or “DIC”, disseminated intravascular coagulation, a disease in which the blood coagulation system is disturbed.
To velja tudi za novorojenčke in bolnike s povečanim tveganjem za trombozo ali “DIK”, diseminirano intravaskularno koagulacijo, bolezen pri kateri je moteno delovanje sistema strjevanja krvi.
This also applies to unknown or emerging viruses and other pathogens.
To velja tudi za neznane ali porajajoče se viruse in druge povzročitelje bolezni.
This also applies when children are breastfed by mothers treated with corticosteroids in case of high dosage or prolonged treatment.
To velja tudi, če otroke dojijo matere, ki so zdravljene s kortikosteroidi v visokih odmerkih ali dlje časa.
This also includes recreational drugs called poppers. if you have low blood pressure (systolic blood pressure less than 95 mmHg) before starting first treatment with this medicine. if you have increased pressure in your pulmonary circulation associated with scarring of the lungs, of unknown cause (idiopathic pulmonary pneumonia).
To vključuje tudi rekreacijske droge, t. i. »poppers«. če imate nizek krvni tlak (sistolični krvni tlak manj kot 95 mm Hg) pred začetkom prvega zdravljenja s tem zdravilom). če imate zvišan tlak v pljučnem krvnem obtoku, povezan z brazgotinjenjem pljuč neznanega vzroka (idiopatsko pljučnico).